- Home
- BNTC vs SEPN Comparison
BNTC vs SEPN Comparison
Compare BNTC & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNTC
- SEPN
- Stock Information
- Founded
- BNTC 1995
- SEPN 2022
- Country
- BNTC United States
- SEPN United States
- Employees
- BNTC N/A
- SEPN 75
- Industry
- BNTC Biotechnology: Pharmaceutical Preparations
- SEPN
- Sector
- BNTC Health Care
- SEPN
- Exchange
- BNTC Nasdaq
- SEPN NYSE
- Market Cap
- BNTC 366.6M
- SEPN 453.2M
- IPO Year
- BNTC N/A
- SEPN 2024
- Fundamental
- Price
- BNTC $14.42
- SEPN $10.41
- Analyst Decision
- BNTC Strong Buy
- SEPN Buy
- Analyst Count
- BNTC 6
- SEPN 4
- Target Price
- BNTC $23.83
- SEPN $27.00
- AVG Volume (30 Days)
- BNTC 72.3K
- SEPN 539.7K
- Earning Date
- BNTC 05-14-2025
- SEPN 08-15-2025
- Dividend Yield
- BNTC N/A
- SEPN N/A
- EPS Growth
- BNTC N/A
- SEPN N/A
- EPS
- BNTC N/A
- SEPN N/A
- Revenue
- BNTC N/A
- SEPN $977,000.00
- Revenue This Year
- BNTC N/A
- SEPN N/A
- Revenue Next Year
- BNTC N/A
- SEPN $526.96
- P/E Ratio
- BNTC N/A
- SEPN N/A
- Revenue Growth
- BNTC N/A
- SEPN 108.76
- 52 Week Low
- BNTC $5.74
- SEPN $4.17
- 52 Week High
- BNTC $17.15
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- BNTC 44.90
- SEPN N/A
- Support Level
- BNTC $14.42
- SEPN N/A
- Resistance Level
- BNTC $17.10
- SEPN N/A
- Average True Range (ATR)
- BNTC 1.20
- SEPN 0.00
- MACD
- BNTC -0.18
- SEPN 0.00
- Stochastic Oscillator
- BNTC 3.66
- SEPN 0.00
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.